Companies › Octapharma
5 active drug programs in 8 registered trials: 6 Phase 3, 2 Phase 4; Immunology, Hematology, Neurology, Infectious disease; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Simoctocog Alfa Coagulation factor VIII exogenous protein | F8 | Phase 4 | Severe Hemophilia A; Hemophilia A | Feb 2027 |
| Human plasma derived antithrombin (Atenativ) Antithrombin (plasma-derived) | SERPINC1 | Phase 3 | Congenital Antithrombin Deficiency; Acquired Antithrombin Deficiency | Dec 2026 |
| OCTA-C1-INH C1 esterase inhibitor (C1-INH) protein replacement | SERPING1 | Phase 3 | Acute Hereditary Angio Edema | Dec 2026 |
| Panzyga, 10% Intravenous human immunoglobulin (IVIG) | – | Phase 3 | Pediatric Chronic Inflammatory Demyelinating Polyneuropathy; Hypogammaglobulinemia | Dec 2028 |
| Newnorm Human normal immunoglobulin (20% subcutaneous formulation) | – | Phase 3 | Primary Immune Deficiency | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05935358 | Simoctocog Alfa | Phase 4 | Severe Hemophilia A | Hematology | Aug 2026 |
| NCT04640142 | Newnorm | Phase 3 | Primary Immune Deficiency | Immunology | Sep 2026 |
| NCT04918173 | Human plasma derived antithrombin (Atenativ) | Phase 3 | Congenital Antithrombin Deficiency | Hematology | Dec 2026 |
| NCT06361537 | OCTA-C1-INH | Phase 3 | Acute Hereditary Angio Edema | Immunology | Dec 2026 |
| NCT05936580 | Simoctocog Alfa | Phase 4 | Hemophilia A | Hematology | Feb 2027 |
| NCT06096116 | Human plasma derived antithrombin (Atenativ) | Phase 3 | Acquired Antithrombin Deficiency | Hematology | Mar 2028 |
| NCT04929236 | Panzyga, 10% | Phase 3 | Pediatric Chronic Inflammatory Demyelinating Polyneuropathy | Neurology | Dec 2028 |
| NCT07220915 | Panzyga, 10% | Phase 3 | Hypogammaglobulinemia | Infectious disease | Dec 2029 |
Swedish Orphan Biovitrum Bioverativ, a Sanofi company Hangzhou Gensciences Biopharmaceutical Gritgen Therapeutics Longbio Pharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.